Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients

BACKGROUND: Endocrine treatment is the most preferable systemic treatment in metastatic breast cancer patients that have had an estrogen receptor (ER) positive primary tumor or metastatic lesions, however, approximately 20% of these patients do not benefit from the therapy and demonstrate further me...

Descripción completa

Detalles Bibliográficos
Autores principales: Babayan, Anna, Hannemann, Juliane, Spötter, Julia, Müller, Volkmar, Pantel, Klaus, Joosse, Simon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776726/
https://www.ncbi.nlm.nih.gov/pubmed/24058649
http://dx.doi.org/10.1371/journal.pone.0075038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776726/
https://www.ncbi.nlm.nih.gov/pubmed/24058649
http://dx.doi.org/10.1371/journal.pone.0075038

Ejemplares similares